However, their potential role in altering the relationship between ARBS or ACE inhibitors and risk of severe/lethal COVID-19 remains unclear: none of the previous studies on the topic assessed cardiovascular diseases severity [26–28], and the two studies that included the use of other antihypertensive drugs into multivariable analyses did not find substantial differences between the adjusted and unadjusted relative risks of death [26, 28]. The gene discussed is ACE; the disease is COVID-19.